Onchilles Pharma, Inc.

SAN DIEGO, CA · Founded 2017 · Biotech · Private

Biologic pan-cancer therapies targeting the ELANE pathway

Claim this profile

Follows are private to you and power your alerts

Updated · onchillespharma.com

Sector
Biotech
Headquarters
SAN DIEGO, CA
Founded
2017
Latest Form D
$3.6M, Jul 2020
Total capital
$3.6M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$3.6M
1 Form D · last Jul 2020
75 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
9 pending · first 2026
Rank in peer group#481 of 1449

Capital timeline

2020FEDERAL ↑EQUITY ↓Cumulative $3.6M1st Form D$3.6M
2020FEDERAL ↑EQUITY ↓Cumulative $3.6M1st Form D$3.6M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$3.6M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#481 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Court TurnerExecutive Officer, DirectorNamed in SEC Form D filings
  • Kevin Li, Ph.D.DirectorNamed in SEC Form D filings
  • Lev Becker, Ph.D.DirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 10
  • GrantedModified Porcine Pancreatic Elastase ProteinsUSPTOUS 12,516,307
  • PendingOncolytic Viruses For Delivery Of Therapeutic PolypeptidesUSPTOApplication PCTUS2025041536
  • PendingPharmaceutical Compositions Comprising Protein ComplexesUSPTOApplication PCTUS2024022956
Show all 10 patent records
  • Modified Porcine Pancreatic Elastase ProteinsJan 6, 2026 · US 12,516,307Granted
  • Oncolytic Viruses For Delivery Of Therapeutic PolypeptidesApplication PCTUS2025041536Pending
  • Pharmaceutical Compositions Comprising Protein ComplexesApplication PCTUS2024022956Pending
  • Pharmaceutical Compositions Comprising Protein ComplexesApplication 63623030Pending
  • Histone H1 Levels As Biomarkers For Cancer TherapyApplication 63547267Pending
  • Pharmaceutical Compositions Comprising Protein ComplexesApplication 63456916Pending
  • Modified Porcine Pancreatic Elastase ProteinsApplication PCTUS2021046453Pending
  • Modified Porcine Pancreatic Elastase ProteinsApplication 63067058Pending
  • Pharmaceutical Compositions Comprising Protein ComplexesApplication 19471684Pending
  • Histone H1 Levels As Biomarkers For Cancer TherapyApplication 19584351Pending
  • Lindy Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
  • NewcelX Ltd.Similar federal contract value in Biotech · null in contracts
  • HCW Biologics Inc.Similar federal contract value in Biotech · null in contracts
  • IHP THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
  • Cytoagents, Inc.Similar federal contract value in Biotech · null in contracts
  • Aromyx CorpSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .